Spindle rotation in human cells is reliant on a MARK2-mediated equatorial spindle-centering mechanism

This work was supported by a Cancer Research UK Career Development Award (C28598/A9787), Biotechnology and Biological Sciences Research Council Project grant (BB/R01003X/1), and a Queen Mary University of London Laboratory startup grant to V.M. Draviam, a Universiti Brunei Darussalam PhD studentship to I. Zulkipli, a Queen Mary University of London PhD studentship to M. Hart, a London Interdisciplinary Biosciences Consortium Biotechnology and Biological Sciences Research Council–Doctoral Training Partnerships PhD studentship to D. Dang (cosupervised by V.M. Draviam and N. Sastry; BB/M009513/1), and an Islamic Development Bank PhD studentship to P. Gul

Algorithm CFP-SFPwith parallel processing

Existing algorithms for finding association rules do not implement parallel processing. This paper proposes CFP-SFP (Creating Frequent Patterns with Set from Frequent Patterns) algorithm with parallel processing. The research involves running CEP-SEP algorithm with one thread and a dozen or so threads that are executed simultaneously. The research was conducted on a computer with one processor and dual-core processor

Daily body weight gains and backfat thickness in fattened pigs of the Spotted Złotnicka breed

Исследовали образование суточных привесов и толщину шпига у 43 хрячков и 63 свинок пёстрой злотницкой породы в возрасте 120, 150, 180, 210 дней. В этом же возрасте хрячки характеризовались существенно высшим весом тела и высшими привесами, чем свинки, однако только до 180 дня. На 120-ый день хрячки имели существенно более толтый шпиг, чем свинки, однако были более ожиренными на 210-ый день. Коэффициенты корреляции между суточными привесами и толщиной шпига были высокими (от о,438**до 0,767**) как для хрячков так и для свинок. Время года влияла на величину суточных привесов, не оказывая влияния на толщину шпига.Formation of daily weight gains and of the backfat thickness in 43 young boars and 63 gilts of the Spotted Złotnicka breed aging 120, 150, 180 and 210 days was investigated. Young boars were of a significantly higher body weight and daily weight gains than gilts; however, the former appeared to be more fatty on the 210th day of life. Coefficients of correlation between daily weight gains and the backfat thickness were high (0.438**-0.767**) both for young boars and gilts. The year season influenced the value of daily weight gains, being ineffective for the backfat thickness

Map Quality Measurements for GNG and SOM based Document Collection Maps

The paper presents a proposal of a set of measures for comparison of maps of document collections as well as preliminary results concerning evaluation of their usefulness and expressive power

Cardiovascular and renal outcomes with empagliflozin in heart failure

BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes